NCT03934372 2026-04-16Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsIncyte CorporationPhase 1/2 Recruiting70 enrolled
NCT01424982 2026-04-15Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaM.D. Anderson Cancer CenterPhase 2 Active not recruiting88 enrolled